LASA filenames:LASA182

Contact: Renate de Jongh

The major cause of hyperthyroidism is Graves disease, which is an auto-immune disorder, or autonomous nodules (either single toxic adenomas or a toxic multinodular goiter, formerly called Plummer disease). Toxic multinodular goiter generally occurs in those aged older than 70 years whereas Graves disease incidence peaks at age 40 to 60 years [1]. For either etiologies treatment is available with either medication, radioactive iodine or surgery of the thyroid gland [2]. The presence of Graves disease may be accompagnied by eye symptoms that may persist after treatment of the hyperfunctioning thyroid [3]. Also, the presence of an auto-immune disease such as Graves disease may predispose the individual to the development of other auto-immune diseases. These are examples why it may be useful to be informed about the presence of hyperthyroidism in the past even if the hyperfunctioning thyroid has been cured.

easurement instruments in LASA
During the medical interview, it was asked whether the respondent had a fast working thyroid. Answer categories were yes, no, do not know. Note: thyroid function was also assessed in 2001 using frozen serum samples of the C-wave. TSH was assessed in all persons (n=1270). When TSH was < 0.3 mU/l or > 4.5 mU/l, then thyroxin (T4) was measured (n=141). When T4 was normal, then T3 was measured (n=49).


LASAC182 / LASAD182 (mvar500; medical interview, in Dutch)

Variable information

(mvar500, pdf)

Availability of information per wave



¹ More information about the LASA data collection waves is available here.

* 2B=baseline second cohort;
3B=baseline third cohort;
MB=migrants: baseline first cohort

Me=data collected in medical interview

Previous use in LASA
Up till now, there are no publications using this variable.


  1. Abraham-Nordling, M., et al., Incidence of hyperthyroidism in Sweden. Eur J Endocrinol, 2011. 165(6): p. 899-905.
  2. Mammen, J.S.R., Thyroid and Aging. Endocrinol Metab Clin North Am, 2023. 52(2): p. 229-243.
  3. Dosiou, C. and A.L. Kossler, Thyroid Eye Disease: Navigating the New Treatment Landscape. J Endocr Soc, 2021. 5(5): p. bvab034.

Date of last update: May, 2023